2019 Forum on Discovery & Development of NASH Drugs

NASH (non-alcoholic steatohepatitis) is a huge unmet clinical need, and behind it is a new drug opportunity that cannot be missed.

The National Institutes of Health estimates that there are currently as many as 30 million people in the United States, or 12% of American adults with NASH. Even more frightening is that as obesity rates rise, liver experts see patients with this disease getting younger and younger. Dr. Leona Kim-Schluger, a hepatologist and professor at the Recanati / Miller Transplantation Institute at Mount Sinai Hospital in New York, said: "Today we see people in their 20s and 30s suffering from NASH. Even in children, they have found it. NASH."

“It is currently estimated that the United States spends $5 billion a year on health care costs associated with the disease, including chemotherapy, transplantation, screening, and hospitalization.” said Health Care economist Home Razavi. He is the Managing Director of the Center for Disease Analysis and is working with health ministers around the world to collect data and help them develop a national health strategy for NASH. “If the disease is not controlled, the cost will increase to $18 billion by 2030.”Industry experts estimate that the global market for these new drugs is $35 billion.

NASH has become a battleground for military strategists. Currently, four companies are working to commercialize drugs to capture NASH: Intercept, Gilead, Elgin and GENFIT in France. All four are in Phase III clinical trials.

In order to promote the research and development of NASH drugs in China and help the pharmaceutical and investment community to understand the latest developments and progress of NASH drug research and development, Drug Times initiated the "2019 Forum on Discovery & Development of NASH Drugs" in March, inviting leading companies and industry leaders. Get together in Shanghai and exchange ideas.